NCT06417710 Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis
| NCT ID | NCT06417710 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Leptomeningeal Metastasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-01-30 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2022-01-30 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this project is to develop and validate a reproducible scorecard for the neurological assessment of patients with leptomeningeal metastases that can be used in clinical trials including such patients, as well as in clinical practice.
Eligibility Criteria
Inclusion Criteria: * Adult patients (18 years or more), female or male * Histologically confirmed diagnosis of extra-CNS primary solid cancer * Diagnosis of leptomeningeal metastases confirmed or probable per EANO ESMO criteria * Performance status compatible with enrolment into clinical trials * Ability to consent * Signed informed consent form from patient * Participation in a parallel clinical trial is allowed in this non-interventional study Exclusion Criteria: * Inability to give informed consent * Inability to adhere to recommended follow-up according to the treating physician Vulnerable participants will not be included.
Frequently Asked Questions
Who can join the NCT06417710 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Leptomeningeal Metastasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06417710 currently recruiting?
Yes, NCT06417710 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Zurich to inquire about joining.
Where is the NCT06417710 trial being conducted?
This trial is being conducted at Houston, United States, Amsterdam, Netherlands, Zurich, Switzerland.
Who is sponsoring the NCT06417710 clinical trial?
NCT06417710 is sponsored by University of Zurich. The trial plans to enroll 200 participants.